Abbott Labs' U.S. nutritional sales fall 1.9% to $579 mil. in Q1, driven by double-digit decline in pediatric nutritionals. Similac infant formula maker says pediatric sales "continued to be impacted by heavy competitive spending." Ross has increased promotional spending, which "is yielding positive results, and we're beginning to see the results of a turnaround in our non-WIC share, which has been under pressure in recent quarters," Divisional VP-Investor Relations John Thomas tells analysts during April 9 call. Launch of DHA/ARA-fortified Similac Advance, other marketing actions expected to drive second-half growth. Abbott's Q1 consolidated sales were $4.19 bil., up 17.7% from year-ago quarter, with net earnings of $854.3 mil., up 16.2% excluding one-time charges in 2001...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
A European Medicines Agency official provided an overview and update of the support the EMA offers developers of innovative products and discussed, among other things, its Innovation Task Force, Quality Innovation Group and a scientific advice pilot for clinical trials.
The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.
